{
    "2018-07-27": [
        [
            {
                "time": "2018-07-31",
                "original_text": "Merck Q2 Earnings & Sales Top on Keytruda Strength",
                "features": {
                    "keywords": [
                        "Merck",
                        "Q2",
                        "Earnings",
                        "Sales",
                        "Keytruda"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-07-31",
                "original_text": "Pharma Stock Roundup: LLY, AGN Post Solid Q2 Results, ABBV's Elagolix Gets FDA Nod",
                "features": {
                    "keywords": [
                        "Pharma",
                        "Stock",
                        "LLY",
                        "AGN",
                        "Q2",
                        "Results",
                        "ABBV",
                        "Elagolix",
                        "FDA"
                    ],
                    "sentiment_score": 0.85,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-07-31",
                "original_text": "Merck Witnessed 5% Growth in Q2 2018",
                "features": {
                    "keywords": [
                        "Merck",
                        "Growth",
                        "Q2",
                        "2018"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-07-31",
                "original_text": "Pfizer’s Q2 2018 Earnings: Analysts’ Estimates",
                "features": {
                    "keywords": [
                        "Pfizer",
                        "Q2",
                        "2018",
                        "Earnings",
                        "Analysts",
                        "Estimates"
                    ],
                    "sentiment_score": 0.6,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "neutral",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2018-07-31",
                "original_text": "Incyte (INCY) to Report Q2 Earnings: What's in the Cards?",
                "features": {
                    "keywords": [
                        "Incyte",
                        "INCY",
                        "Q2",
                        "Earnings"
                    ],
                    "sentiment_score": 0.5,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "biotechnology"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "neutral",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2018-07-31",
                "original_text": "New Research: Key Drivers of Growth for ICU Medical, A. Schulman, Verso, Eli Lilly, Spectrum Pharmaceuticals, and Intuit — Factors of Influence, Major Initiatives and Sustained Production",
                "features": {
                    "keywords": [
                        "Research",
                        "Drivers",
                        "Growth",
                        "ICU",
                        "Medical",
                        "A.",
                        "Schulman",
                        "Verso",
                        "Eli",
                        "Lilly",
                        "Spectrum",
                        "Pharmaceuticals",
                        "Intuit",
                        "Initiatives",
                        "Production"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "healthcare",
                        "materials",
                        "technology"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            }
        ]
    ]
}